查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2105684

全球失智症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Dementia Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 223 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球失智症治療市場預計將從2025年的210.1億美元成長至2034年的412.4億美元，2026年至2034年的複合年成長率（CAGR）為7.78%。隨著全球人口老化和失智症相關疾病盛行率的上升，該市場正經歷顯著成長。失智症治療包括藥物治療、認知護理計畫、支持性醫療保健服務以及旨在改善患者預後和生活品質的數位健康解決方案。人們對神經系統疾病的認知不斷提高、診斷能力的增強以及醫療保健服務的普及，正在推動早期療育和綜合疾病管理的發展。

製藥公司正大力投資創新療法的研發，旨在延緩疾病進展並控制症狀。生物標記研究、神經影像學和個人化醫療的進步正在提高診斷準確性，並為更有效的治療策略提供支援。各國政府和醫療機構正在加大對失智症認知宣傳、看護者支持和專科醫療服務的投入。隨著研究機構和生技公司之間合作的不斷深化，療法創新也持續加速發展。

隨著我們對神經退化性疾病的科學認知不斷加深，前景一片光明。人工智慧輔助診斷、精準醫療和新型生物療法有望在未來幾年徹底改變失智症的治療現狀。社區醫療保健計畫的完善、數位化監測技術的進步以及支持性護理服務的普及，將顯著改善病患管理。持續的醫療保健研究和投資將推動全球失智症治療市場的永續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、阻礙因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長領域和區域趨勢，以更深入地了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球失智症治療市場：依適應症分類

  • 市場分析、洞察與預測
  • 阿茲海默症失智症
  • 血管性失智症
  • 路易氏體失智症
  • 額顳葉型失智症（FTD）
  • 與帕金森氏症相關的失智症
  • 其他

第5章：全球失智症治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 膽鹼酯酶抑制劑
  • NMDA受體拮抗劑
  • 單胺氧化酶抑制劑
  • 同時服用的藥物
  • 其他

第6章：全球失智症治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 經皮吸收貼片
  • 注射藥物

第7章 全球失智症治療市場：依分銷管道分類

  • 市場分析、洞察與預測
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章 全球失智症治療市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第9章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第10章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Eisai Co. Ltd
    • Eli Lilly And Company
    • Novartis AG
    • Daiichi Sankyo
    • AbbVie Inc
    • Lundbeck
    • Biogen Inc
    • Cipla Ltd
    • Sun Pharmaceutical
    • Viatris Inc
    • F. Hoffmann-La Roche
    • Pfizer Inc
    • Johnson & Johnson（Janssen）
    • Otsuka Pharmaceutical
    • Merz Therapeutics
    • TauRx Pharmaceuticals
    • Alzheon Inc
    • AC Immune SA
    • Cassava Sciences
    • Annovis Bio
簡介目錄
Product Code: VMR112119278

The global dementia treatment market size is expected to reach USD 41.24 Billion in 2034 from USD 21.01 Billion in 2025, growing at a CAGR of 7.78 during 2026-2034.This market is witnessing substantial growth as the global aging population continues to increase and the prevalence of dementia-related disorders rises. Dementia treatment includes pharmaceutical therapies, cognitive care programs, supportive medical services, and digital health solutions designed to improve patient outcomes and quality of life. Growing awareness of neurological disorders, improved diagnostic capabilities, and expanding healthcare access are encouraging earlier intervention and comprehensive disease management.

Pharmaceutical companies are investing heavily in research and development of innovative therapies targeting disease progression and symptom management. Advances in biomarker research, neuroimaging, and personalized medicine are improving diagnostic accuracy and supporting more effective treatment strategies. Governments and healthcare organizations are increasing investments in dementia awareness, caregiver support, and specialized healthcare services. Growing collaboration between research institutions and biotechnology companies continues accelerating therapeutic innovation.

The future outlook remains highly encouraging as scientific understanding of neurodegenerative diseases continues advancing. Artificial intelligence-assisted diagnostics, precision medicine, and novel biological therapies are expected to transform dementia care in the coming years. Expansion of community healthcare programs, digital monitoring technologies, and supportive care services will improve patient management. Continued research and healthcare investment will drive sustainable growth within the global dementia treatment market.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Indication

  • Alzheimer's Disease Dementia
  • Vascular Dementia
  • Lewy Body Dementia
  • Frontotemporal Dementia (FTD)
  • Parkinson's Disease Dementia
  • Others

By Drug Class

  • Cholinesterase Inhibitors
  • NMDA Receptor Antagonist
  • MAO Inhibitors
  • Combination Drug
  • Others

By Route of Administration

  • Oral
  • Transdermal Patch
  • Injectable

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

COMPANIES PROFILED

  • Eisai Co. Ltd., Eli Lilly and Company, Novartis AG, Daiichi Sankyo, AbbVie Inc., Lundbeck, Biogen Inc., Cipla Ltd., Sun Pharmaceutical, Viatris Inc., F. Hoffmann-La Roche, Pfizer Inc., Johnson & Johnson (Janssen), Otsuka Pharmaceutical, Merz Therapeutics, TauRx Pharmaceuticals, Alzheon Inc., AC Immune SA, Cassava Sciences, Annovis Bio

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL DEMENTIA TREATMENT MARKET: BY INDICATION 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Indication
  • 4.2. Alzheimer's Disease Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Vascular Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Lewy Body Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Frontotemporal Dementia (FTD) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Parkinson's Disease Dementia Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DEMENTIA TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Drug Class
  • 5.2. Cholinesterase Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. NMDA Receptor Antagonist Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. MAO Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Combination Drug Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DEMENTIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Route Of Administration
  • 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Transdermal Patch Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DEMENTIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Distribution Channel
  • 7.2. Hospital Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Retail Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Online Pharmacy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL DEMENTIA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 8.1. Regional Outlook
  • 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.2.1 By Indication
    • 8.2.2 By Drug Class
    • 8.2.3 By Route Of Administration
    • 8.2.4 By Distribution Channel
    • 8.2.5 United States
    • 8.2.6 Canada
    • 8.2.7 Mexico
  • 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.3.1 By Indication
    • 8.3.2 By Drug Class
    • 8.3.3 By Route Of Administration
    • 8.3.4 By Distribution Channel
    • 8.3.5 United Kingdom
    • 8.3.6 France
    • 8.3.7 Germany
    • 8.3.8 Italy
    • 8.3.9 Russia
    • 8.3.10 Rest Of Europe
  • 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.4.1 By Indication
    • 8.4.2 By Drug Class
    • 8.4.3 By Route Of Administration
    • 8.4.4 By Distribution Channel
    • 8.4.5 India
    • 8.4.6 Japan
    • 8.4.7 South Korea
    • 8.4.8 Australia
    • 8.4.9 South East Asia
    • 8.4.10 Rest Of Asia Pacific
  • 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.5.1 By Indication
    • 8.5.2 By Drug Class
    • 8.5.3 By Route Of Administration
    • 8.5.4 By Distribution Channel
    • 8.5.5 Brazil
    • 8.5.6 Argentina
    • 8.5.7 Peru
    • 8.5.8 Chile
    • 8.5.9 Rest of Latin America
  • 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 8.6.1 By Indication
    • 8.6.2 By Drug Class
    • 8.6.3 By Route Of Administration
    • 8.6.4 By Distribution Channel
    • 8.6.5 Saudi Arabia
    • 8.6.6 UAE
    • 8.6.7 Israel
    • 8.6.8 South Africa
    • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

  • 9.1. Recent Developments
  • 9.2. Company Categorization
  • 9.3. Supply Chain & Channel Partners (based on availability)
  • 9.4. Market Share & Positioning Analysis (based on availability)
  • 9.5. Vendor Landscape (based on availability)
  • 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL DEMENTIA TREATMENT INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Company Profiles
    • 10.2.1 Eisai Co. Ltd
    • 10.2.2 Eli Lilly And Company
    • 10.2.3 Novartis AG
    • 10.2.4 Daiichi Sankyo
    • 10.2.5 AbbVie Inc
    • 10.2.6 Lundbeck
    • 10.2.7 Biogen Inc
    • 10.2.8 Cipla Ltd
    • 10.2.9 Sun Pharmaceutical
    • 10.2.10 Viatris Inc
    • 10.2.11 F. Hoffmann-La Roche
    • 10.2.12 Pfizer Inc
    • 10.2.13 Johnson & Johnson (Janssen)
    • 10.2.14 Otsuka Pharmaceutical
    • 10.2.15 Merz Therapeutics
    • 10.2.16 TauRx Pharmaceuticals
    • 10.2.17 Alzheon Inc
    • 10.2.18 AC Immune SA
    • 10.2.19 Cassava Sciences
    • 10.2.20 Annovis Bio